Organigram Holdings Inc. (TSE:OGI – Free Report) – Equities research analysts at Alliance Global Partners cut their FY2025 EPS estimates for shares of Organigram in a research note issued to investors on Wednesday, August 13th. Alliance Global Partners analyst A. Grey now forecasts that the company will earn $0.09 per share for the year, down from their prior estimate of $0.12. The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Alliance Global Partners also issued estimates for Organigram’s Q1 2026 earnings at ($0.03) EPS.
Organigram Stock Performance
Shares of Organigram stock opened at C$2.01 on Friday. The firm has a market cap of C$248.32 million, a PE ratio of -4.25, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The firm’s 50-day simple moving average is C$1.95 and its 200-day simple moving average is C$1.77. The company has a debt-to-equity ratio of 3.07, a quick ratio of 2.62 and a current ratio of 3.36. Organigram has a 1 year low of C$1.22 and a 1 year high of C$2.84.
About Organigram
Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.
Read More
- Five stocks we like better than Organigram
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 Energy Stocks to Gain Exposure to the Carbon Capture Boom
- How to Calculate Return on Investment (ROI)
- AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- The Real Reason Ford Stock Is Rallying—Can It Keep Going?
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.
